Full-Time

Immunology Sales Specialist

Nephrology

Posted on 10/6/2025

Mallinckrodt

Mallinckrodt

1,001-5,000 employees

Specialty pharmaceutical developer, manufacturer, distributor

No salary listed

Raleigh, NC, USA + 1 more

More locations: Richmond, VA, USA

In Person

Overnight travel is required (~50%), may vary depending on the region/area.

Category
Sales & Account Management (1)
Requirements
  • Bachelor’s Degree, and 5+ years’ experience required in the following area: Nephrology
  • In lieu of a bachelor’s degree, will consider either an associate’s degree and 7+ years, OR 10+ years, of successful, proven pharmaceutical or industry equivalent experience within Nephrology.
  • Current experience within the territory and customer knowledge is a requirement.
  • Experience Selling Biologics to Specialty Physicians in Nephrology is required.
  • A valid motor vehicle operator's license.
Responsibilities
  • Meet or exceed all established Region sales plan and expense plan goals and objectives, by developing and implementing strategies specific to the assigned Region/Area.
  • Establish and maintain professional relationships with targeted opinion leaders and physicians.
  • Maintain an updated working knowledge of Mallinckrodt Pharmaceuticals products and relevant disease states, specifically within the Nephrology therapeutic area.
  • Effectively develops a Territory Business Plan, plans all workdays and weeks, established call plans and prepares for all sales calls to meet or exceed goals and objectives.
  • Develop and implement special programs within territory to maximize sales opportunities, i.e., speakers’ bureau programs, local conferences/congresses, symposia, etc.
  • Develop and/or maintain permanent customer records.
  • Complete assigned administrative tasks in a timely, accurate, legible, and organized manner.
  • Communicate a current, effective, and accurate sales presentation to customers.
  • Present a professional sales image in all business matters.
  • Carry out duties and responsibilities in compliance with applicable regulations and Pharma guidelines and operate assigned sales territory within established sales and/or corporate policies, procedures, and standards.
  • Attend regional and national conferences throughout the year.

Mallinckrodt is a global specialty pharmaceutical company that develops, manufactures, and distributes drugs and therapies for complex and rare conditions, serving healthcare providers, hospitals, and patients mainly in the United States and Europe. Its products target areas such as autoimmune diseases, rare diseases, and critical care, and the business rests on research and development, manufacturing, and sales. The company differentiates itself through a patient-centric approach, a commitment to integrity, ongoing innovation, and collaboration, grounded in more than 150 years of experience and a focus on ESG initiatives. Its goal is to improve the health and well-being of patients worldwide by delivering specialty medicines and advancing sustainable practices.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Hazelwood, Missouri

Founded

1867

Simplify Jobs

Simplify's Take

What believers are saying

  • Merger with Endo completed, forming NYSE-listed therapeutics leader by Q4 2025.
  • Reduced debt 47% to $865.6M and grew Acthar Gel sales 14.2% in 2024.
  • Sold Therakos for $925M, optimizing portfolio for specialty pharmaceuticals.

What critics are saying

  • Endo merger integration disrupts operations, overloading with $6.7B debt.
  • Therakos sale drops immunotherapy revenue, losing edge to Amgen immediately.
  • Acthar Gel's $300K pricing triggers DOJ probe and $500M fines within 18 months.

What makes Mallinckrodt unique

  • Mallinckrodt specializes in Acthar Gel for autoimmune diseases over 150 years.
  • Focuses on rare diseases and critical care therapies for underserved patients.
  • Launched Acthar Gel self-injectable to improve patient adherence and convenience.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Mallinckrodt who can refer or advise you

Benefits

Performance Bonus

Relocation Assistance

Growth & Insights and Company News

Headcount

6 month growth

3%

1 year growth

3%

2 year growth

3%
PR Newswire
Nov 10th, 2025
Par Health Completes Spin-Off from Mallinckrodt, Creating an Independent Leader in Generic Pharmaceuticals and Sterile Injectables

Launches as Top 15 U.S. Generic Drug Manufacturer, Largest U.S. Producer of Active Pharmaceutical Ingredients and Premier U.S. Producer of Sterile Injectables...

Contract Pharma
Aug 6th, 2025
Mallinckrodt Names Christiana Stamoulis President and CFO

Mallinckrodt plc appointed Christiana Stamoulis as President and Chief Financial Officer, effective September 22, 2025.

Stock Titan
Aug 1st, 2025
Mallinckrodt-Endo Merger Creates Therapeutics Leader

Mallinckrodt and Endo have completed a merger to form a global therapeutics leader. The companies will combine their generics businesses and Endo's sterile injectables business, which will be spun off as an independent company by Q4 2025. The newly branded company will be listed on the New York Stock Exchange following the spin-off.

The Business Journals
Jul 25th, 2025
Mallinckrodt Reaches $7B Merger Milestone

Mallinckrodt has reached a milestone in a $7 billion merger deal.

Sharecast
Mar 13th, 2025
Mallinckrodt and Endo to merge in $6.7bn deal

Pharmaceutical firm Mallinckrodt said on Thursday that it has agreed to merge with Endo in a $6.7bn deal.

INACTIVE